Obstructive sleep apnoea and continuous positive
airway pressure therapy for patients with
non-alcoholic fatty liver disease: abridged
secondary publication
DSC Hui1, SSS Ng1, GLH Wong1, WCW Chu2, A Chan3, VWS Wong1
1 Department of Medicine and Therapeutics, The Chinese University of Hong Kong
2 Department of Imaging & Interventional Radiology, The Chinese University of Hong Kong
3 Department of Pathology, The Chinese University of Hong Kong
1. Of 226 patients with non-alcoholic fatty liver
disease (NAFLD) who underwent home sleep
test, 222 had evidence of obstructive sleep apnoea
(OSA) with respiratory event index (REI) of
≥5/hour.
2. Both therapeutic and subtherapeutic continuous positive airway pressure therapy (CPAP) had similar effects on non-invasive markers of liver fat, steatosis, and fibrosis after 6 months of treatment. Percentage change in weight after 6 months correlated with the change in transient elastography controlled attenuation parameter, which is a marker of liver fat (B=3.249, SE=0.873, 95% Wald CI=1.538-4.960, P<0.001).
3. CPAP alone is unlikely to alter NAFLD activities in patients with concomitant OSA. The additional role of weight reduction through lifestyle modification deserves further investigation.
2. Both therapeutic and subtherapeutic continuous positive airway pressure therapy (CPAP) had similar effects on non-invasive markers of liver fat, steatosis, and fibrosis after 6 months of treatment. Percentage change in weight after 6 months correlated with the change in transient elastography controlled attenuation parameter, which is a marker of liver fat (B=3.249, SE=0.873, 95% Wald CI=1.538-4.960, P<0.001).
3. CPAP alone is unlikely to alter NAFLD activities in patients with concomitant OSA. The additional role of weight reduction through lifestyle modification deserves further investigation.